---
title: "InnoCare climbs 6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304214967.md"
description: "InnoCare Pharma rose 5.85% to HK$11.77. Down 6.36% over ten sessions."
datetime: "2026-11-04T05:33:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304214967.md)
  - [en](https://longbridge.com/en/news/304214967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304214967.md)
generator: "portal-rs"
---

# InnoCare climbs 6%

InnoCare Pharma (9969.HK) climbed nearly **6%** in Hong Kong trading to **HK$11.77**.

The stock is down 6.36% over the past ten sessions and sits 21.97% above its 52-week low of HK$9.650.

The Hang Seng Index is up 2.72% over the past five sessions and down 7.44% year to date.

The biotechnology industry index rose 6.0% over the same period.

The company reported first-three-quarter revenue of 2.099 billion yuan, up 88.21% from a year earlier, and net income of 648 million yuan, swinging to a profit.

Separately, ICP-B161, a novel bispecific antibody targeting TL1A and IL-23p19 developed for inflammatory bowel disease and other autoimmune conditions, has completed first-patient dosing in a Phase I trial. InnoCare also presented clinical data at the ESMO Congress showing an 89.5% response rate for orelabrutinib-based combination therapy in treatment-naive marginal zone lymphoma patients.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)

## Related News & Research

- [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md)
- [InnoCare's Orelabrutinib Combination Shows 89.5% Response Rate in Phase 2 Marginal Zone Lymphoma Trial](https://longbridge.com/en/news/303302918.md)
- [InnoCare Pharma (SEHK:9969) Climbed, What Is Driving Attention Today?](https://longbridge.com/en/news/303497906.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization](https://longbridge.com/en/news/303068907.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**